Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06127407
What this trial is testing

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Who this might be right for
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC 136
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Testing effectiveness (Phase 2)Looking for participantsNCT07304011
What this trial is testing

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Who this might be right for
Acute Myeloid Leukemia
University of California, Davis 28
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Testing effectiveness (Phase 2)Looking for participantsNCT05588141
What this trial is testing

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Who this might be right for
Brain TumorCancer
National Cancer Institute (NCI) 96
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Testing effectiveness (Phase 2)WithdrawnNCT02987010
What this trial is testing

Phase 2 Study of IDH305 in Low Grade Gliomas

Who this might be right for
Glioma
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)UnknownNCT03666559
What this trial is testing

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Who this might be right for
Recurrent IDH1/2 Mutated Glioma
Assistance Publique - Hôpitaux de Paris 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Large-scale testing (Phase 3)Looking for participantsNCT05907057
What this trial is testing

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia (AML)
Servier Affaires Médicales 245
Testing effectiveness (Phase 2)Active Not RecruitingNCT06081829
What this trial is testing

Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Who this might be right for
Cholangiocarcinoma Non-resectableCholangiocarcinoma Metastatic
Servier 12
Testing effectiveness (Phase 2)Looking for participantsNCT06501625
What this trial is testing

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Who this might be right for
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier 52
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06782542
What this trial is testing

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaIDH1 Mutation
Justin Watts, MD 16
Early research (Phase 1)Active Not RecruitingNCT02381886
What this trial is testing

IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Who this might be right for
Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals 166
Testing effectiveness (Phase 2)Looking for participantsNCT07286292
What this trial is testing

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Who this might be right for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.) 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Study completedNCT02719574
What this trial is testing

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome
Forma Therapeutics, Inc. 336
Next Page